Methods of making bempedoic acid and compositions of the same
The invention provides methods of preparing 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and methods of making a pharmaceutical material comprising a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid. Also provided are compositions and pharmaceutical materials including a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid as well as methods of treating various diseases and conditions using the compositions and pharmaceutical materials.
1. A method of preparing a compound of formula (V):
the method comprising:
(a) contacting ethyl isobutyrate with a substituted 5-chloropentane in the presence of a first base to form a compound of formula (I):
wherein the substituted 5-chloropentane is selected from the group consisting of 1-bromo-5-chloropentane and 1-iodo-5-chloropentane;
(b) contacting the compound of formula (I) with a salt of formula [M] + [X] − to form a compound of formula (II):
wherein [M] + is selected from the group consisting of Li + , Na + and K + , and [X] − is selected from the group consisting of Br − and I − ;
(c) contacting the compound of formula (II) with toluenesulfonylmethyl isocyanide in the presence of a second base to form a first intermediate, and contacting the first intermediate with an acid to form a compound of formula (IV):
and
(d) contacting the compound of formula (IV) with a reducing agent to form a second intermediate, and contacting the second intermediate with a hydrolyzing base to form a compound of formula (V).
2. The method of claim 1 , wherein in step (a), the first base is selected from the group consisting of lithium diisopropylamide, lithium bis(trimethylsilyl)amide, sodium hydride, sodium amide, lithium amide, and lithium tetramethylpiperidide.
3. The method of claim 1 , wherein in step (a), contacting ethyl isobutyrate with the substituted 5-chloropentane is conducted at a temperature in the range of about −20° C. to about 0° C.
4. The method of claim 1 , wherein in step (a), less than about 1% by weight of the substituted 5-chloropentane remains after forming the compound of formula (I).
5. The method of claim 1 , wherein in step (a), the molar ratio of ethyl isobutyrate to the substituted 5-chloropentane is from about 1.1:1 to about 1.21:1.
6. The method of claim 1 , wherein in step (b), contacting the compound of formula (I) with the salt of formula [M] + [X] − is conducted in a solvent comprising one or more of acetone, 2-butanone, methyl isobutyl ketone, and tetrahydrofuran, wherein M is selected from the group consisting of Li, Na and K, and X is selected from the group consisting of Br and I.
7. The method of claim 6 , wherein in step (b), the solvent comprises less than about 3% by weight water.
8. The method of claim 1 , wherein in step (b), contacting the compound of formula (I) with the salt of formula [M] + [X] − is conducted at a temperature in the range of about 78° C. to about 82° C., wherein M is selected from the group consisting of Li, Na and K, and X is selected from the group consisting of Br and I.
9. The method of claim 1 , wherein in step (b), contacting the compound of formula (I) with the salt of formula [M] + [X] − comprises contacting the compound of formula (I) with about 1.1 molar equivalents of the salt of formula [M] + [X] − based on the molar amount of the compound of formula (I), wherein M is selected from the group consisting of Li, Na and K, and X is selected from the group consisting of Br and I.
10. The method of claim 1 , wherein in step (b), the salt of formula [M] + [X] − is sodium iodide.
11. The method of claim 1 , wherein in step (d), the reducing agent is selected from the group consisting of sodium borohydride, sodium cyanoborohydride, cerium borohydride, zinc borohydride and diisobutylaluminum hydride.
12. The method of claim 1 , wherein in step (d), contacting the compound of formula (IV) with a reducing agent comprises contacting the compound of formula (IV) with about 0.35 molar equivalents of the reducing agent based on the molar amount of the compound of formula (IV).
13. The method of claim 1 , wherein in step (d), the hydrolyzing base is sodium hydroxide.
14. The method of claim 1 , wherein in step (d), contacting the second intermediate with a hydrolyzing base to form a compound of formula (V) is conducted in a solution; and the method further comprises adjusting the pH of the solution comprising the compound of formula (V) to between about 3 to about 7.
15. The method of claim 1 , wherein in step (d), contacting the compound of formula (IV) with a reducing agent to form a second intermediate, and contacting the second intermediate with a hydrolyzing base to form a compound of formula (V) is conducted in a single reaction vessel.
16. A method of preparing a compound of formula (V):
the method comprising:
(a) contacting ethyl isobutyrate with a substituted 5-chloropentane in the presence of a first base to form a compound of formula (I):
wherein the substituted 5-chloropentane is selected from the group consisting of 1-bromo-5-chloropentane and 1-iodo-5-chloropentane;
(b) contacting the compound of formula (I) with a salt of formula [M] + [X] − to form a compound of formula (II):
wherein [M] + is selected from the group consisting of Li + , Na + and K + , and [X] − is selected from the group consisting of Br − and I − ;
(c) contacting the compound of formula (II) with toluenesulfonylmethyl isocyanide in the presence of a second base to form a first intermediate, and contacting the first intermediate with an acid to form a compound of formula (IV):
and
(d) contacting the compound of formula (IV) with about 0.25 to about 0.7 molar equivalents of sodium borohydride to form a second intermediate, and contacting the second intermediate with a hydrolyzing base to form a compound of formula (V).
17. A method of preparing a crystalline form of the compound of formula (V):
the method comprising:
(a) contacting ethyl isobutyrate with a substituted 5-chloropentane in the presence of a first base to form a compound of formula (I):
wherein the substituted 5-chloropentane is selected from the group consisting of 1-bromo-5-chloropentane and 1-iodo-5-chloropentane;
(b) contacting the compound of formula (I) with a salt of formula [M] + [X] − to form a compound of formula (II):
wherein [M] + is selected from the group consisting of Li + , Na + and K + , and [X] − is selected from the group consisting of Br − and I − ;
(c) contacting the compound of formula (II) with toluenesulfonylmethyl isocyanide in the presence of a second base to form a first intermediate, and contacting the first intermediate with an acid to form a compound of formula (IV):
(d) contacting the compound of formula (IV) with a reducing agent to form a second intermediate, and contacting the second intermediate with a hydrolyzing base to form a compound of formula (V); and
(e) purifying the compound of formula (V) to provide a pharmaceutical material, wherein purifying comprises crystallizing the compound of formula (V) to provide a crystalline form of the compound of formula (V) and the pharmaceutical material comprises greater than about 99% of the crystalline form of the compound of formula (V) based on the total weight of the pharmaceutical material.
18. The method of claim 17 , wherein the method further comprises recrystallizing the crystalline form of the compound of formula (V).
19. The method of claim 18 , wherein crystallizing the compound of formula (V) and recrystallizing the crystalline form of the compound of formula (V) comprise crystallizing the compound of formula (V) in a mixture of solvents comprising ethyl acetate and water, and recrystallizing the crystalline form of the compound of formula (V) in a mixture of solvents comprising ethyl acetate and water.
20. The method of claim 17 , wherein the pharmaceutical material has a melting point onset temperature as determined by differential scanning calorimetry in a range between about 90° C. to about 94° C.